ストックスクリーナーアプリを入手
21.53
14.36%
-3.61
Arcus Biosciences Inc (RCUS) 最新ニュース
Arcus Biosciences (NYSE:RCUS) Shares Gap DownHere's What Happened - MarketBeat
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $32.00 at HC Wainwright - MarketBeat
Arcus Biosciences Target of Unusually Large Options Trading (NYSE:RCUS) - MarketBeat
HC Wainwright & Co. Maintains Arcus Biosciences (RCUS) Buy Recommendation - Nasdaq
Arcus Calls Quits On Anti-TIGIT Candidate After Phase III Termination - Citeline News & Insights
Arcus shifts effort, bears down on would-be ‘anchor’ in RCC - BioWorld MedTech
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug - Benzinga
H.C. Wainwright raises Arcus Biosciences stock price target to $32 on lower expenses - Investing.com Canada
Why Arcus Biosciences just reversed its 287% eight-month winning streak - MSN
Why Did Arcus Biosciences Stock Slump 10% Today? - Asianet Newsable
Truist Securities lowers Arcus Biosciences stock price target on trial failure - Investing.com
RCUS: HC Wainwright & Co. Raises Price Target for Arcus Bioscien - GuruFocus
Truist Securities Adjusts Arcus Biosciences Price Target to $30 From $39, Maintains Buy Rating - marketscreener.com
Arcus Biosciences (RCUS) Shares Decline Over 11% in Recent Tradi - GuruFocus
Arcus scraps late-stage cancer trial after weak survival data - Reuters
Arcus Biosciences (RCUS) Drops After Halting Phase 3 Cancer Tria - GuruFocus
Arcus Biosciences Stock (RCUS) Collapses 17% after Failed Stomach Cancer Study - TipRanks
GILD: Gilead and Arcus End STAR-221 Study Due to Lack of Efficac - GuruFocus
Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment -- Update - marketscreener.com
Arcus Biosciences Discontinuing Gastric, Esophogeal Cancer Candidate Trial; Shares Fall - marketscreener.com
Gilead and Arcus halt late-stage study for anti-TIGIT cancer drug - Seeking Alpha
Arcus Biosciences to Discontinue Phase 3 Trial of Potential Cancer Treatment - marketscreener.com
Arcus Biosciences stock falls after discontinuing phase 3 cancer study By Investing.com - Investing.com Australia
Arcus Biosciences Discontinues Phase 3 STAR-221 Study - TradingView — Track All Markets
Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology Portfolio - TradingView — Track All Markets
Gilead, Arcus scrap late-stage trial of cancer drug combo - Yahoo
Arcus Biosciences (NYSE: RCUS) ends STAR-221, backs casdatifan and I&I pipeline into 2028 - Stock Titan
Arcus cancels work on Gilead-partnered cancer combo after trial setback - Yahoo Finance
Decliners Report: Why Arcus Biosciences Inc stock attracts global investors2025 Volatility Report & Weekly Watchlist for Consistent Profits - moha.gov.vn
Avoiding Lag: Real-Time Signals in (RCUS) Movement - news.stocktradersdaily.com
Arcus Biosciences Announces New Employment Inducement Grants - marketscreener.com
Arcus Biosciences (NYSE: RCUS) sets $25.80 inducement grant under 2020 plan - Stock Titan
Arcus Biosciences (NYSE:RCUS) Reaches New 1-Year HighWhat's Next? - MarketBeat
Is Arcus Biosciences Stock Built to Withstand a Pullback? - Trefis
Fisher Asset Management LLC Decreases Stock Holdings in Arcus Biosciences, Inc. $RCUS - MarketBeat
Insider Selling: Arcus Biosciences (NYSE:RCUS) President Sells 82,997 Shares of Stock - MarketBeat
Arcus Biosciences, Inc. $RCUS Shares Acquired by Tema Etfs LLC - MarketBeat
Arcus Biosciences (NYSE:RCUS) Downgraded by Wall Street Zen to Sell - MarketBeat
Is Arcus Biosciences Inc. stock cheap by valuation metricsWeekly Market Outlook & Low Risk High Win Rate Stock Picks - Newser
Can Arcus Biosciences Inc. stock ride next bull market cycleShort Setup & Real-Time Market Trend Scan - Newser
Decheng Capital LLC Has $1.30 Million Holdings in Arcus Biosciences, Inc. $RCUS - MarketBeat
How Arcus Biosciences Inc. stock performs during market turbulenceJuly 2025 Review & Weekly High Potential Alerts - Newser
What is the fair value estimate for Arcus Biosciences Inc. stock in 2025Earnings Overview Report & Safe Entry Momentum Stock Tips - Newser
How Arcus Biosciences Inc. stock behaves in tightening cyclesJuly 2025 Levels & Weekly High Conviction Ideas - Newser
RCUS: Casdatifan shows superior efficacy in RCC, with pivotal trials and strong financial backing - TradingView
Arcus Biosciences (NYSE:RCUS) Hits New 52-Week HighStill a Buy? - MarketBeat
Arcus Biosciences, Inc. $RCUS Shares Purchased by Geode Capital Management LLC - MarketBeat
How Arcus Biosciences Inc. stock compares with market leadersJuly 2025 Analyst Calls & Safe Entry Point Alerts - Newser
Arcus Biosciences (NYSE:RCUS) CAO Alexander Azoy Sells 1,900 Shares - MarketBeat
Arcus Biosciences stock hits 52-week high at 26.32 USD By Investing.com - Investing.com Australia
Arcus Biosciences stock hits 52-week high at 26.32 USD - Investing.com
SG Americas Securities LLC Buys 17,111 Shares of Arcus Biosciences, Inc. $RCUS - MarketBeat
How dovish Fed policy supports Arcus Biosciences Inc. stock2025 Pullback Review & Daily Stock Trend Reports - Newser
Pancreatic Cancer Pipeline Drugs Insights Report 2025 | - openPR.com
Arcus Biosciences Executive Sells Shares - TradingView
Discipline and Rules-Based Execution in RCUS Response - news.stocktradersdaily.com
Arcus Biosciences (NYSE:RCUS) Stock Price Expected to Rise, Bank of America Analyst Says - MarketBeat
B of A Securities Maintains Arcus Biosciences (RCUS) Neutral Recommendation - Nasdaq
RCUS: B of A Securities Raises Price Target to $26, Maintains Ne - GuruFocus
Arcus Biosciences (NYSE:RCUS) Sets New 12-Month HighShould You Buy? - MarketBeat
An Intrinsic Calculation For Arcus Biosciences, Inc. (NYSE:RCUS) Suggests It's 39% Undervalued - Yahoo Finance
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):